AKT1 is altered in 0.93% of lung carcinoma patients [2].

AKT1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is altered in 5.47% of lung carcinoma patients [2].

ALK is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ALK status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

ATM is altered in 7.0% of lung carcinoma patients [2].

ATM is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATM status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ATR is altered in 3.86% of lung carcinoma patients [2].

ATR is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRAF is altered in 5.06% of lung carcinoma patients [2].

BRAF is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain BRAF status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

BRCA1 is altered in 3.45% of lung carcinoma patients [2].

BRCA1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BRCA2 is altered in 4.55% of lung carcinoma patients [2].

BRCA2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BRCA2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CCND1 is altered in 2.51% of lung carcinoma patients [2].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CCND1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK12 is altered in 2.4% of lung carcinoma patients [2].

CDK12 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK12 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK4 is altered in 3.4% of lung carcinoma patients [2].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDK6 is altered in 1.05% of lung carcinoma patients [2].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDK6 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CDKN2A is altered in 12.84% of lung carcinoma patients [2].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CDKN2A status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CHEK2 is altered in 1.58% of lung carcinoma patients [2].

CHEK2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CHEK2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

CSF1R is altered in 1.78% of lung carcinoma patients [2].

CSF1R is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CSF1R status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is altered in 22.35% of lung carcinoma patients [2].

EGFR is an inclusion eligibility criterion in 3 clinical trials for lung carcinoma, of which 2 are open and 1 is closed. Of the trials that contain EGFR status and lung carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 2 (2 open) [3].

EPCAM is altered in 0.53% of lung carcinoma patients [2].

EPCAM is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPCAM status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is altered in 3.91% of lung carcinoma patients [2].

ERBB2 is an inclusion eligibility criterion in 4 clinical trials for lung carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ERBB2 status and lung carcinoma as inclusion criteria, 4 are phase 2 (3 open) [3].

ERBB3 is altered in 1.92% of lung carcinoma patients [2].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EXO1 is altered in 3.81% of lung carcinoma patients [2].

EXO1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EXO1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FANCA is altered in 3.02% of lung carcinoma patients [2].

FANCA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FANCA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR1 is altered in 3.72% of lung carcinoma patients [2].

FGFR1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR2 is altered in 1.17% of lung carcinoma patients [2].

FGFR2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FGFR3 is altered in 1.55% of lung carcinoma patients [2].

FGFR3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGFR3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT1 is altered in 4.17% of lung carcinoma patients [2].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT3 is altered in 2.25% of lung carcinoma patients [2].

FLT3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is altered in 4.12% of lung carcinoma patients [2].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR is altered in 3.94% of lung carcinoma patients [2].

KDR is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KDR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KIT is altered in 2.19% of lung carcinoma patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is altered in 28.63% of lung carcinoma patients [2].

KRAS is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MET is altered in 4.95% of lung carcinoma patients [2].

MET is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MET status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH1 is altered in 0.87% of lung carcinoma patients [2].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MLH3 is altered in 3.17% of lung carcinoma patients [2].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MRE11A is altered in 1.5% of lung carcinoma patients [2].

MRE11A is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MRE11A status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH2 is altered in 1.84% of lung carcinoma patients [2].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH3 is altered in 1.36% of lung carcinoma patients [2].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MSH6 is altered in 2.14% of lung carcinoma patients [2].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MST1R is altered in 1.3% of lung carcinoma patients [2].

MST1R is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MST1R status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MTOR is altered in 3.65% of lung carcinoma patients [2].

MTOR is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NBN is altered in 2.46% of lung carcinoma patients [2].

NBN is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NBN status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRAS is altered in 1.15% of lung carcinoma patients [2].

NRAS is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NRG1 is altered in 1.15% of lung carcinoma patients [2].

NRG1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRG1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

NTRK1 is altered in 3.89% of lung carcinoma patients [2].

NTRK1 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK1 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NTRK2 is altered in 1.97% of lung carcinoma patients [2].

NTRK2 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK2 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

NTRK3 is altered in 5.69% of lung carcinoma patients [2].

NTRK3 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain NTRK3 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

PALB2 is altered in 1.84% of lung carcinoma patients [2].

PALB2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PALB2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PCNA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PCNA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRA is altered in 3.66% of lung carcinoma patients [2].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is altered in 3.06% of lung carcinoma patients [2].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CA is altered in 6.47% of lung carcinoma patients [2].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS1 is altered in 1.79% of lung carcinoma patients [2].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PMS2 is altered in 2.12% of lung carcinoma patients [2].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLD1 is altered in 2.14% of lung carcinoma patients [2].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

POLE is altered in 4.19% of lung carcinoma patients [2].

POLE is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLE status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAD51C is altered in 0.88% of lung carcinoma patients [2].

RAD51C is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAD51C status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RAF1 is altered in 1.0% of lung carcinoma patients [2].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RET is altered in 3.42% of lung carcinoma patients [2].

RET is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain RET status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RFC1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC4 is altered in 0.06% of lung carcinoma patients [2].

RFC4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RFC5 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RFC5 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ROS1 is altered in 4.77% of lung carcinoma patients [2].

ROS1 is an inclusion eligibility criterion in 2 clinical trials for lung carcinoma, of which 2 are open and 0 are closed. Of the trials that contain ROS1 status and lung carcinoma as inclusion criteria, 2 are phase 2 (2 open) [3].

RPA1 is altered in 2.46% of lung carcinoma patients [2].

RPA1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA3 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA3 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RPA4 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RPA4 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

SSBP1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SSBP1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC1 is altered in 1.85% of lung carcinoma patients [2].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TSC2 is altered in 3.75% of lung carcinoma patients [2].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VHL is altered in 0.47% of lung carcinoma patients [2].

VHL is an inclusion eligibility criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VHL status and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].